Replimune (REPL) Treasury Shares (2018 - 2026)
Replimune (REPL) posted Treasury Shares of $5.5 million for Q1 2026, down 2.72% sequentially from $5.7 million in Q4 2025, and up 52.53% YoY from $3.6 million in Q1 2025.
Replimune (REPL) Treasury Shares (2018 - 2026) Analysis & Trends
Replimune has reported Treasury Shares for 7 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Treasury Shares rose 52.53% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 52.53% YoY) and the FY2026 annual result came in at $5.5 million, up 52.53% from the prior year.
- Treasury Shares declined to $5.5 million in Q1 2026 per REPL's latest filing, from $5.7 million in the prior quarter.
- Over five years, Treasury Shares peaked at $5.7 million in Q4 2025 and troughed at $826213.0 in Q1 2022.
- A 5-year average of $3.0 million and a median of $2.4 million in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares jumped 5071.91% in 2022, then soared 46.07% in 2025.
- Over 5 years, Treasury Shares stood at $1.4 million in 2022, then surged by 50.77% to $2.0 million in 2023, then soared by 71.06% to $3.5 million in 2024, then surged by 62.2% to $5.7 million in 2025, then declined by 2.72% to $5.5 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $5.5 million, $5.7 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.51 Mn |
| Mar 31, 2026 | 5.51 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 5.11 Mn |
| Sep 30, 2025 | 5.11 Mn |
| Jun 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 5.23 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | 3.49 Mn |
| Dec 31, 2024 | 3.49 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 2.04 Mn |
| Dec 31, 2023 | 2.04 Mn |